SARTORIUS STEDIM, DEAR TO THE CORE (SELL; -29% DOWNSIDE)
23/02/21 -" Sartorius Stedim Biotech (Sell, France) ranks as a top-notch asset, with industry-leading return metrics (FY20 ROE of 26% vs 14% for AV peers). Since we noted its phenomenal run almost two years ..."
Pages
68
Language
English
Published on
23/02/21
You may also be interested by these reports :
02/11/26
Too hot to step in Exactly 12 months ago, SKAN (REDUCE; -3% DOWNSIDE) (Reduce, Switzerland) issued a profit warning citing multiple project delays, ...
02/11/26
emeis keeps delivering: +6% organic growth over nine months, group occupancy above 90% for the first time. The disposal plan is done with over €1.1bn ...
30/10/26
Amplifon’s Q3 sales met expectations, while adjusted EBITDA missed. All regions recorded growth. Profitability improved, but full-year guidance ...
29/10/26
Clariane’s Q3 confirmed the operating turnaround: organic growth accelerated to 4.9%, occupancy reached 93% and France finally joined the party. The ...